Companies › Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
1 active drug program in 2 registered trials: 2 Phase 1; Ophthalmology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DF-003 ALPK1 inhibitor | ALPK1 | Phase 1 | Healthy; ROSAH | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05997641 | DF-003 | Phase 1 | Healthy | Other | Oct 2026 |
| NCT06395285 | DF-003 | Phase 1 | ROSAH | Ophthalmology | Nov 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.